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ABSTRACT After initiation of an infective cycle, spread of virus infection can occur
in two fundamentally different ways: (i) viral particles can be released into the exter-
nal environment and diffuse through the extracellular space until they interact with
a new host cell, and (ii) virions can remain associated with infected cells, promoting
the direct passage between infected and uninfected cells that is referred to as direct
cell-to-cell transmission. Although evidence of cell-associated transmission has accu-
mulated for many different viruses, the ability of members of the genus Pestivirus to
use this mode of transmission has not been reported. In the present study, we used
a novel recombinant virus expressing the envelope glycoprotein E2 fused to
mCherry fluorescent protein to monitor the spreading of bovine viral diarrhea virus
(BVDV) (the type member of the pestiviruses) infection. To demonstrate direct cell-
to-cell transmission of BVDV, we developed a cell coculture system that allowed us
to prove direct transmission from infected to uninfected cells in the presence of
neutralizing antibodies. This mode of transmission requires cell-cell contacts and
clathrin-mediated receptor-dependent endocytosis. Notably, it overcomes antibody
blocking of the BVDV receptor CD46, indicating that cell-to-cell transmission of the
virus involves the engagement of coreceptors on the target cell.
IMPORTANCE BVDV causes one of the most economically important viral infections
for the cattle industry. The virus is able to cross the placenta and infect the fetus,
leading to the birth of persistently infected animals, which are reservoirs for the
spread of BVDV. The occurrence of persistent infection has hampered the efficacy of
vaccination because it requires eliciting levels of protection close to sterilizing im-
munity to prevent fetal infections. While vaccination prevents disease, BVDV can be
detected if animals with neutralizing antibodies are challenged with the virus. Virus
cell-to-cell transmission allows the virus to overcome barriers to free virus dissemina-
tion, such as antibodies or epithelial barriers. Here we show that BVDV exploits cell-
cell contacts to propagate infection in a process that is resistant to antibody neutral-
ization. Our results provide new insights into the mechanisms underlying the
pathogenesis of BVDV infection and can aid in the design of effective control strate-
gies.
KEYWORDS CD46, E2, bovine viral diarrhea virus, cell-to-cell transmission,
endocytosis, pestiviruses, reporter genes, surface receptor, virus entry
Bovine viral diarrhea virus (BVDV) is a positive-strand RNA virus that infects cattleand causes major economic losses to the livestock industry worldwide (1). Together
with classical swine fever virus (CSFV) and border disease virus (BDV) of sheep, BVDV
belongs to the Pestivirus genus in the family Flaviviridae. The family also comprises
flaviviruses, which are arthropod-borne viruses, including important human pathogens
such as dengue virus, yellow fever virus, and tick-borne encephalitis virus; hepacivi-
ruses, including hepatitis C virus (HCV); and pegiviruses (2). Virus genomes contain a
single open reading frame (ORF) that is translated into a polyprotein. For pestiviruses,
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the polyprotein is cleaved by viral and cellular proteases into the following individual
viral proteins: Npro-C-Erns-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B (3, 4). Pestivirus
particles consist of a lipid bilayer with envelope glycoproteins Erns, E1, and E2 sur-
rounding the nucleocapsid, composed of the capsid protein C and the RNA genome (5,
6). E2 determines the cellular tropism of the virus, which is directly related to the
interaction of E2 and cellular receptors (7, 8). In turn, it has been shown that a soluble
version of the E2 protein inhibits viral infection and that E2 is the main antigenic
determinant of infection and induces the production of neutralizing antibodies (9–11).
Cytopathic (cp) and noncytopathic (ncp) biotypes of BVDV differ in their capacity to
induce cell death in culture (12). Adult cattle are most commonly infected by ncpBVDV
biotypes that cause acute infections and can cross the placenta of the dam to infect the
fetus, leading to congenital malformations and abortion or to the birth of persistently
infected (PI) animals. PI animals are immunotolerant to BVDV and shed the virus,
spreading the disease in cattle populations (13, 14). cpBVDV biotypes arise in PI cattle,
from recombination events in the infecting ncpBVDV genome, and are associated with
the development of fatal mucosal disease (15, 16). BVDV control requires combining
vaccination with removal of PI animals. While vaccination is effective at the herd level,
it is not completely effective in every individual animal (10). In fact, animals with
neutralizing antibodies can develop viremia and shed virus in nasal secretions when
challenged with the homologous virus (17, 18). However, the strategies that BVDV uses
to overcome the host antibody response still remain unclear.
The viral infection cycle begins with the entry of free viral particles into susceptible
cells through interaction with receptors and coreceptors that trigger clathrin-mediated
endocytosis, allowing the internalization of the virion in an endosomal vesicle (19–21).
A pH drop in the endosome triggers the fusion of virus and the cell membranes, which
results in the release of genomic RNA into the cytoplasm of the infected cell (22–24).
It has been shown for many enveloped viruses that, after initiation of an infective cycle,
spread of infection can occur by two different mechanisms. On the one hand, progeny
viruses are released from the cell and diffuse through the extracellular space until they
interact with a new host cell. Alternatively, virions can remain associated with infected
cells and propagate to neighboring cells at sites of direct cell-cell contact (25–27). The
latter mode of spreading is known as direct cell-to-cell transmission. There are many
attractive advantages associated with direct cell-to-cell transmission that can be ex-
ploited by viruses. In general, cell-associated transmission is considered more rapid and
efficient because it obviates rate-limiting steps of cell-free spread: the cycle of release,
diffusion, and entry can occur quickly at cell-cell contact sites. Moreover, viruses that
move across tight and adherens junctions are protected from the effects of neutralizing
antibodies and other immune system components (28). Therefore, a common feature
of cell-associated transmission of viruses is the ability to spread infection even in the
presence of neutralizing antibodies, which completely block the entry of free viruses. In
recent years, evidence has accumulated that many animal viruses can efficiently
propagate through direct cell-to-cell transmission (29, 30). Neurotropic viruses exploit
neurochemical synapses to spread between connected neurons. For instance, herpes-
virus membrane proteins engage kinesin motors for anterograde transport of vesicles
containing fully assembled virus particles toward axon termini. Virus egress involves
fusion of the transport vesicle with the axonal membrane at the exit sites (31). Other
viruses induce the formation of cell-cell contacts, referred to as virological synapses,
through the interaction of virus glycoproteins with receptors on the target cell. Next,
the assembly and egress of the viral progeny become polarized toward contact sites.
For HIV, integrins and intercellular adhesion molecules surround virological synapses,
and polarization of virus assembly is directed by the rearrangement of the cytoskeleton
and the secretory machinery (32). Viruses that use actin polymerization as a driving
force for spread include murine leukemia virus and vaccinia virus (30). The murine
leukemia virus envelope glycoprotein engages receptors on the target cell to establish
filopodial bridges that transport the virus toward the noninfected cell (33). On the other
hand, the extracellular form of vaccinia virus that remains associated with the infected
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cell induces polymerization of actin tails that propel the virus toward the target cell (34).
Within the Flaviviridae family, it has been reported that cell-to-cell transmission of HCV
depends on the expression of two host proteins that also function as postattachment
receptors for the entry of free virus, namely, claudin-1 and occludin, both of which are
present in tight junction cell-cell contacts (35–38).
So far, the ability of any member of the genus Pestivirus to spread directly from
infected to noninfected cells has not been reported. In the present study, we developed
a novel recombinant BVDV strain expressing the envelope glycoprotein E2 fused to
mCherry fluorescent protein that allowed us to monitor the spread of infection. Using
a fluorescence microscopy-based approach to quantify spreading of the reporter virus
in a coculture of producer and target cells expressing fluorescent proteins of contrast-
ing colors, we demonstrated the ability of BVDV to propagate in the presence of
antibodies that neutralize free viruses. Furthermore, our approach unambiguously
shows that direct transmission from cell to cell requires the interaction of E2 with cell
receptors and clathrin-mediated endocytosis by the target cell.
RESULTS
Development of a reporter virus expressing a fusion of mCherry to E2 envelope
protein. Different recombinant pestiviruses have been developed that express foreign
genes as reporter proteins that are released from the viral polyprotein by proteolytic
cleavage and serve to monitor viral infection (39–41). To follow the spread of BVDV
infection in the present study, we designed a recombinant virus that carries a fusion of
mCherry fluorescent protein to the E2 envelope protein. We constructed a pair of
cytopathic and noncytopathic infectious clones in which the mCherry coding sequence
is inserted between the protease cleavage site at the C terminus of E1 and the
beginning of E2 (Fig. 1A). Tagging of E2 at this position was previously shown to have
no impact on BVDV growth kinetics and particle formation (42, 43). Next, full-length
genomic RNAs were synthesized by in vitro transcription, using the recombinant
infectious clones as templates, and transfected into MDBK cells. Three days after RNA
transfection, mCherry expression was detected by fluorescence microscopy for both cp-
and ncpBVDV/mCherry-E2 (Fig. 1B and data not shown). Immunostaining with an NS3
antibody was used to detect BVDV replication and showed that the NS3 antibody-
stained cells expressed mCherry, indicating that recombinant RNAs were competent for
viral replication. Next, we collected supernatants of transfected cells and infected a new
monolayer of MDBK cells to assess the production of infectious viruses (Fig. 1C). The day
after infection, expression of mCherry was readily observed under a fluorescence
microscope and was confined to single cells for both cytopathic and noncytopathic
viruses. At 2 days, the cytopathic virus formed large foci of infection, and cytopathic
effect was evident 3 days after infection. In turn, spread of infection by the noncyto-
pathic virus resulted in an intact monolayer of cells expressing mCherry by day 3. In
addition, we used confocal microscopy to evaluate the degree of colocalization be-
tween mCherry and E2 in cells infected with the recombinant virus and stained with a
monoclonal antibody (MAb) against E2. Image analysis produced Pearson and Manders
coefficients that indicated colocalization between mCherry and antibody staining
signals, suggesting that mCherry remains fused to E2 (Fig. 1D). Finally, to address the
impact of mCherry insertion on the production of infectious virus, we compared the
specific infectivities of RNAs transcribed from parental or BVDV/mCherry-E2 infectious
clones (44). The viral titers determined at 2 days for the supernatants of MDBK cells
transfected with equal amounts of the RNAs were similar, suggesting that fusion of
mCherry to E2 does not significantly impact the assembly of infectious particles.
Altogether, these results confirm that the N terminus of E2 is a suitable site for the
insertion of foreign proteins into the pestivirus genome.
BVDV/mCherry-E2 uses the authentic entry pathway of BVDV for entry into
MDBK cells. Interaction of the BVDV envelope protein E2 with cell-specific receptors
triggers clathrin-mediated endocytosis, and acidification of the endosomal compart-
ment is required for release of the genome into the cytoplasm of the infected cell
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(19–21). Given that insertion of mCherry at the N terminus of E2 might affect the
function of the envelope protein, altering the entry route of the recombinant virus, we
compared the sensitivities of parental BVDV and BVDV/mCherry-E2 to different chem-
ical and molecular entry inhibitors. In order to evaluate the use of BVDV receptors, we
employed a soluble version of E2, obtained using a baculovirus system for recombinant
expression, to compete with the entry of the virus (Fig. 2A and B). The recombinant
protein reduced BVDV cytopathic effect in a dose-dependent manner, reaching total
























FIG 1 Design and construction of recombinant BVDV carrying a fusion of mCherry fluorescent protein to the viral envelope protein E2. (A)
Schematic representation of BVDV/mCherry-E2 genome. The mCherry sequence was inserted between the protease cleavage site at the end of
E1 and the beginning of E2. Coding sequences for nonstructural proteins are indicated in blue and those for structural proteins in orange. Host
signal peptidase cleavage sites are indicated with arrows and viral protease cleavage sites with arrowheads. (Top) Insertion of the 90-amino-acid
DNAJC14 subdomain (Jiv90) within NS2 into the cytopathic (cp) variant of BVDV/mCherry-E2 is indicated with a gray box. (Bottom) Sequence of
amino acids around the mCherry insertion. (B) mCherry expression coincides with NS3 expression. Representative images of MDBK cells
transfected with in vitro-transcribed RNA of BVDV/mCherry-E2 are shown. Cells were fixed at 3 days posttransfection and stained with a
monoclonal antibody against NS3 and with DAPI. (C) Time course of infection of MDBK cells with cytopathic and noncytopathic BVDV/mCherry-E2.
Images of fixed cells stained with DAPI were acquired at 24, 48, and 72 h postinfection. (D) mCherry colocalizes with E2. Confocal microscopy
images of MDBK cells infected with BVDV/mCherry-E2 and stained with a monoclonal antibody against E2 are shown. Split-channel images of the
boxed areas are presented in the bottom row. Colocalization analysis values are as follows: Pearson’s R, 0.68; Manders M1, 0.959; Manders M2,
0.984; and Costes P, 1.00.
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inhibition at 1 g/ml (Fig. 2C and D). In addition, to address the usage of a BVDV-
specific cell receptor, we used MAbs against CD46 to block virus infection (8) (Fig. 2E).
The inhibitory effects of recombinant E2 or CD46 MAbs on parental BVDV and BVDV/






















































































FIG 2 Soluble E2 and MAbs against CD46 block BVDV infection. (A) Expression of recombinant E2. A truncated
version of E2 fused to a 6His tag at the C terminus was produced in a soluble form by use of a baculovirus
expression system and purified by affinity chromatography. Fractions eluted from an IMAC column with increasing
concentrations of imidazole were resolved by SDS-PAGE, and elution of the recombinant protein was detected by
Coomassie blue staining of the gel. (B) Western blotting using anti-6His tag (left lane) and anti-BVDV (right lane)
antibodies confirmed the identity of the protein. (C) Functionality of recombinant E2 tested in a cytopathic effect
reduction assay. MDBK cells were preincubated with increasing amounts of the recombinant protein and then
infected with cpBVDV at an MOI of 0.01 (BVDV; top rows) or left uninfected (no inf; bottom row). At 3 to 4 days
postinfection, cells were fixed and stained with crystal violet to estimate the extent of the cytopathic effect. (D)
Inhibition of BVDV infection by recombinant E2. Data collected from the cytopathic effect reduction assay were
used to plot the log concentration versus the percentage of inhibition. Inhibitory concentrations were estimated
from nonlinear regression fitting of the curve. (E) Plot of the log concentration versus the percentage of inhibition
for cytopathic effect reduction assay of BVDV infection in MDBK cells preincubated with increasing amounts of a
mix of MAbs BVD/CA 17 and 26 against CD46. (F) Representative images of cells infected with parental BVDV or
BVDV/mCherry-E2 and fixed at 24 h. Cells infected with the parental virus were identified by immunostaining of E2
(green channel in left panel). Expression of mCherry allowed direct visualization of cells infected with BVDV/
mCherry-E2 (red channel in right panel). (G) Soluble E2 and CD46 MAbs completely inhibited infection by parental
BVDV and BVDV/mCherry-E2. The bar graph shows the quantification of the inhibition of BVDV entry into MDBK
cells preincubated with recombinant E2 (rE2) or CD46 MAbs (CD46). Cells were infected with parental BVDV or
BVDV/mCherry-E2 and processed as described for panel F. Bars represent the percentages of infected cells relative
to control cells for infection with parental BVDV (WT; black bars) or BVDV/mCherry-E2 (red bars).
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soluble protein or the antibodies before infection with the virus. At 24 h postinfection,
entry was assessed by fluorescence microscopy using E2 antibody staining or mCherry
expression to detect infection with parental or recombinant virus, respectively (Fig. 2F).
We observed that both soluble E2 and CD46 MAbs completely blocked entry for
parental BVDV and BVDV/mCherry-E2 (Fig. 2G). Next, we evaluated the dependence on
clathrin-mediated endocytosis and acidification of the endosomal compartment for
internalization by using chlorpromazine and ammonium chloride treatments, respec-
tively. MDBK cells were pretreated with increasing amounts of chlorpromazine or
ammonium chloride for 1 h before infection and then infected in the presence of the
drug. After 2 h, cells were washed to remove the drug and noninternalized viruses, and
the effect of drug treatment on virus entry was quantified by fluorescence microscopy
(Fig. 3A and data not shown). We observed for both viruses that entry was blocked to
similar extents, and in a dose-dependent manner, in cells treated with chlorpromazine
(Fig. 3B). Similar results were obtained for ammonium chloride treatment (Fig. 3C). To
further confirm the endocytic internalization of the virus, we quantified entry of BVDV
into cells expressing a control or dominant negative version of Eps15, which is specific
for clathrin-mediated endocytosis. To this end, we transduced MDBK cells with lenti-
viruses expressing fusions of green fluorescent protein (GFP) to DIIIΔ2 (control) and
EH29 (dominant negative) Eps15 constructs. Uptake of transferrin conjugated to Texas
Red was used as a control for clathrin-dependent endocytosis. As expected, we
observed that the fluorescent dye was efficiently internalized into cells expressing
DIIIΔ2 Eps15, while internalization into cells expressing EH29 Eps15 was diminished
(Fig. 3D), indicating that loss of clathrin-mediated endocytosis function is achieved by
expressing the dominant negative construct in MDBK cells. In agreement with the
results for chlorpromazine treatment, entry of both parental BVDV and BVDV/
mCherry-E2 was blocked in MDBK cells expressing dominant negative Eps15 (Fig. 3E
and F). Altogether, these results indicate that BVDV/mCherry-E2 uses the authentic
entry pathway of BVDV to infect MDBK cells.
BVDV spread is resistant to antibody neutralization. Virus spread can rely on two
mechanisms: release of free virus particles and direct cell-to-cell transmission, which is
often resistant to antibody neutralization. To experimentally address whether cell-to-
cell transmission contributes to dissemination of BVDV, we assayed spread in the
presence of BVDV neutralizing antibodies. To this end, we first generated a BVDV
neutralizing serum by immunizing mice with soluble protein E2. The serum showed a
90% neutralization titer (NT90) of 104 and completely blocked infection with BVDV
when preincubated with the virus stock (Fig. 4A and B). Antibodies of the IgG isotype
purified from the serum and commercial monoclonal antibodies to E2 were also
neutralizing, with estimated NT90s of 103 and 104, respectively (Fig. 4B). Next, we set up
conditions to assess spreading of BVDV in the presence of neutralizing antibodies.
MDBK cells were infected with BVDV/mCherry-E2, and at 2 h postinfection, noninternal-
ized virus was removed by exhaustive washing and fresh medium or medium containing
anti-E2 serum, IgG antibodies, or monoclonal antibodies was added (Fig. 4C). Imaging of
infected cells at 2 days postinfection showed that the virus was able to spread both in the
control and in the presence of neutralizing antibodies. However, spread was noticeably
confined in the presence of neutralizing antibodies, as quantified by a significant reduc-
tion in the total percentage of infected cells compared to that for the control (Fig. 4D
and E). To verify that dissemination of free viruses was blocked throughout the
experiment, the supernatants of control cells and cells incubated in the presence of
antibodies were collected at the end of the experiment and used to infect a new
monolayer of MDBK cells. Infected cells were observed only after infection with the
supernatant from control cells, indicating that free virus released from infected cells
was completely neutralized in the assay (Fig. 4E). Therefore, the differences in the foci
formed in the presence of neutralizing antibodies and in the control can be explained
by free viruses not contributing to the spread of infection.
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To further confirm that spreading in the presence of neutralizing serum did not arise
from cell-free dissemination of neutralization escape variants that might be present in
the virus stock, we initiated infection by transfection of BVDV/mCherry-E2 RNA into
MDBK cells. At 4 h posttransfection, cells were washed and infection was allowed to
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FIG 3 Comparison of the entry routes of parental BVDV and BVDV/mCherry-E2. (A) Effect of entry inhibitors on BVDV infection.
Representative images of cells treated with increasing concentrations of NH4Cl and infected with BVDV/mCherry E2 are shown. (B and C)
Dose-dependent inhibition of BVDV entry by chlorpromazine and NH4Cl. Bar graphs show the quantification of the inhibition of entry of
parental BVDV or BVDV/mCherry-E2 into MDBK cells treated with increasing concentrations of drugs. Bars represent the means and
standard deviations of the percentages of infected cells relative to control cells for three independent experiments. At least 500 infected
cells were counted for the control in each of the experiments. (D) Overexpression of dominant negative Eps15 in MDBK cells decreases
clathrin-dependent uptake of transferrin. Representative images of the uptake of Texas Red-labeled transferrin (red channel) into MDBK
cells overexpressing a control (DIIIΔ2) or dominant negative (EH29) construct of Eps15 (green channel) are shown. (E) Representative
images of the entry of BVDV/mCherry-E2 (red channel) into MDBK cells overexpressing a control (DIIIΔ2) or dominant negative (EH29)
construct of Eps15 (green channel). (F) Overexpression of dominant negative Eps15 blocks infection with BVDV. The bar graph shows the
quantification of virus entry into cells overexpressing a control (DIIIΔ2) or dominant negative (EH29) construct of Eps15. The percentage
of cells overexpressing control Eps15 and infected with parental BVDV (black bars) or BVDV/mCherry-E2 (red bars) was set to 100%. Bars
for cells overexpressing dominant negative Eps15 represent the percentage of infection relative to that for control Eps15-overexpressing
cells.
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FIG 4 Spreading of BVDV is resistant to antibody neutralization of free viruses. (A) Titration of neutralizing antibodies by cytopathic effect
reduction assay. An E2 immune serum was obtained from mice immunized with recombinant E2. A stock of cpBVDV was incubated with
serial dilutions of the serum and then used to infect MDBK cells. At 3 to 4 days postinfection, cells were fixed and stained with crystal violet
to estimate the extent of the cytopathic effect. (B) Data collected by cytopathic effect reduction assay were used to plot the log dilution
versus the percentage of inhibition for serum against E2 (E2 serum), the corresponding IgG fraction (E2 IgG), and a MAb against E2
(E2 MAb). Antibody titers were estimated from nonlinear regression fitting of the curve. (C) Schematic representation of the experimental
setup to compare spreading of the virus in MDBK cells cultured in control medium or in the presence of neutralizing antibodies. (D) BVDV
spread resists antibody neutralization of free virus. MDBK cells were infected with BVDV/mCherry-E2 (MOI  0.1), and the infection was
allowed to proceed for 48 h in control medium or in the presence of neutralizing antibodies. Representative images of virus spread (red
channel) in cells cultured in control medium or medium containing neutralizing antibodies (top panels) and of the reinfection of fresh
MDBK cells with the supernatants harvested at the end of the experiment (bottom panels) are shown. (E) Bar graph showing quantification
of the absolute percentage of infected cells. Bars represent the means and standard deviations for three independent images. Data were
analyzed by one-way ANOVA with Dunnett’s posttest (**, P  0.01; ***, P  0.001). (F) (Top) Schematic representation of the experimental
(Continued on next page)
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stocks, spread of infection was observed both in the control and in the presence of
neutralizing serum, and foci of infection were confined under the latter condition (Fig.
4F). Altogether, our results indicate that BVDV spread is resistant to antibody neutral-
ization of free viruses.
Cell-to-cell transmission of viruses can occur across cell contact sites requiring direct
contact of the primary infected cell with neighboring cells. To gain insight into the
mechanism underlying spread of BVDV in the presence of neutralizing serum, we used
a transwell coculture system to physically separate infected producer cells from target
cells. Producer cells infected with BVDV/mCherry-E2 were plated on a cell culture insert,
target cells were plated on the bottom of the well, and then the cells were cultured for
2 days in control medium or in medium containing neutralizing serum (Fig. 5A). Virus
spread from producer to target cells was analyzed by fluorescence microscopy. As
expected, infected target cells could be observed in the control transwell setup. In
contrast, when neutralizing serum was added to the medium, no target cells were
infected despite total infection of producer cells (Fig. 5B). Therefore, the results ob-
tained by use of the transwell coculture system indicate that spread of BVDV in the
presence of neutralizing antibodies requires direct cell-cell contact.
Direct cell-to-cell transmission is the main mechanism of BVDV spread. In order
to unequivocally identify spread from infected producer cells to noninfected target
cells, we set up a coculture system of producer MDBK cells persistently infected with
the noncytopathic biotype of BVDV/mCherry-E2 and target MDBK cells stably express-
ing GFP, generated by lentivirus transduction and fluorescence-activated cell sorting.
Producer and target cells were plated at a 1:4 ratio and cocultured in control medium
or medium containing neutralizing antibodies (Fig. 6A). After 3 days, infection of target
cells was evident in fluorescence microscopy images of cocultures. To quantify spread-
ing, we devised an automated computer-assisted image analysis method (Fig. 6B and
C) and used the ratio between the number of infected target cells and the total number
of target cells as a measure of spreading from producer to target cells. Spreading was
assessed using serum, purified IgG, or monoclonal antibodies to neutralize free virus. In
all cases, we observed that spreading in the presence of neutralizing antibodies was
reduced by around one-third with respect to the control level (Fig. 6D and E). On one
hand, this result indicates that in the presence of antibodies the mechanism supporting
spreading is the direct cell-to-cell transmission of the virus. On the other hand, since
FIG 4 Legend (Continued)
setup to assess virus spreading in the presence of neutralizing serum in an infection started by transfection of in vitro-transcribed RNA
into MDBK cells. (Bottom) Representative images of cells transfected with the RNA of BVDV/mCherry-E2 (red channel) and cultured in























FIG 5 Antibody-resistant spreading of BVDV requires cell-cell contact. (A) Schematic representation of the transwell
assay. Infected MDBK cells on a transwell membrane were cocultured with target MDBK cells in control medium
or in the presence of neutralizing serum to test the dependence of spreading on cell-cell contact. (B) Representative
images of the transwell assay for control spreading (left panels) and spreading in the presence of neutralizing
serum (right panels). Producer cells were infected with BVDV/mCherry-E2 (red channel). Spreading from infected
(producer) cells to noninfected (target) cells was assessed at 2 days postinfection.
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antibody neutralization blocks spreading of free viruses, the comparison of spreading
in the control and in the presence of antibodies allowed us to estimate the contribution
of dissemination of free virus versus direct cell-to-cell transmission to BVDV spread. Our
results indicate that direct cell-to-cell transmission accounts for nearly two-thirds of
spreading. In a similar manner, when producer cells were infected with cpBVDV/
mCherry-E2 and cocultured with noninfected target cells for 2 days, we observed that
direct cell-to-cell transmission was the main mechanism contributing to BVDV spread
(Fig. 6E).
Spread of BVDV from producer to target cells uses receptor-mediated clathrin-
dependent endocytosis. We next asked whether cell-associated transmission of BVDV
depends on the use of virus receptors. To address this question, we infected MDBK cells
with BVDV/mCherry, and after washing of the noninternalized virus, cells were incu-






















































FIG 6 Cell-to-cell transmission of BVDV is the main mechanism contributing to spreading. (A) Schematic representation of the
experimental setup of the coculture system of producer cells persistently infected with ncpBVDV/mCherry-E2 (red) and noninfected target
cells expressing GFP (green). Spreading from producer cells to target cells can be distinguished by the expression of both GFP and
mCherry (yellow). (B) Identification of infected target cells by automated image analysis. The number of target cells (GFP; green channel)
infected with BVDV/mCherry-E2 (mCherry; red channel) was identified on a cell monolayer (DAPI; blue channel) by using the analytical
tools of ImageJ software. Appropriate thresholding and binary processing of the red, green, and blue channels identified objects
corresponding to mCherry expression in cpBVDV/mCherry-E2-infected cells, GFP expression in target cells, and cell nuclei, respectively
(segmentation). We next used logical operators and “analyze particles” tools to number target cells (GFP and DAPI masks) and infected
target cells (mCherry and GFP and DAPI masks). (C) Superpositioning of the result mask (yellow) identifying infected target cells with the
split-channel images of the boxed area in panel B. (D) Direct cell-to-cell spread of BVDV. Representative images of spreading of BVDV into
target cells in cocultures of producer (mCherry; red channel) and target (GFP; green channel) cells in control medium or medium
containing neutralizing antibodies are shown. (E) Quantification of spreading. Bars represent the means and standard deviations of the
percentages of target cells infected with ncp (top) or cp (bottom) BVDV/mCherry-E2 (% spread). At least a thousand total target cells were
counted for each condition. Data were analyzed by one-way ANOVA with Dunnett’s posttest (*, P  0.05; **, P  0.01; ***, P  0.001).
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the entry of free virus and the infection was allowed to proceed for 2 days. We observed
that foci of infection were confined to single cells after treatment with E2, suggesting
that receptor occupancy prevents spreading (Fig. 7B). In striking contrast, foci of
infection spread after the specific block of CD46, yielding a percentage of infected cells
that was reduced to an extent similar to that for the treatment with neutralizing
antibodies with respect to the control (compare Fig. 7B and Fig. 4E), implying that the
function of CD46 is limited to the entry of free viruses. The requirement of receptor





































































































FIG 7 Cell-to-cell transmission of BVDV requires both receptor recognition and clathrin-dependent endocytosis. (A)
Representative images of virus spread (red channel) in cells cultured in control medium or medium containing soluble
E2 (rE2) or CD46 MAbs (CD46). (B) Bar graph showing quantification of the absolute percentage of infected cells. Bars
represent the means and standard deviations for three independent images. Data were analyzed by one-way ANOVA
with Dunnett’s post-test (***, P  0.001). (C) Representative images of producer (red channel; ncpBVDV/mCherry-E2) and
target (green channel; GFP) MDBK cells in control cocultures (left) or cocultures in the presence of soluble E2 (middle)
or CD46 MAbs (right). (D) Quantification of spreading. Bars represent the means and standard deviations of the
percentages of infected target cells. At least a thousand total target cells were counted for each condition. Data were
analyzed by one-way ANOVA with Dunnett’s post-test (*, P  0.05; ***, P  0.001). (E) Quantification of spreading from
producer cells infected with ncpBVDV/mCherry-E2 (red channel) to target CRIB cells expressing GFP (green channel). Bars
represent the means and standard deviations of the percentages of infected target cells. At least a thousand total target
cells were counted for each condition. Data were analyzed by the unpaired t test (***, P  0.001). (F) Representative
images of producer MDBK cells cocultured with target MDBK cells overexpressing a control (DIIIΔ2) or dominant negative
(EH29) Eps15 construct in the presence of neutralizing serum. (G) Quantification of spreading. Bars represent the means
and standard deviations of the percentages of infected target cells. At least a thousand total target cells were counted
for each condition. Data were analyzed by the unpaired t test (***, P  0.001).
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system. To this end, we set up cocultures in control medium or medium supplemented
with soluble E2 or CD46 MAbs. We confirmed that soluble E2 completely blocked
spreading, while efficient cell-to-cell transmission was measured in the presence of
CD46 MAbs (Fig. 7C and D). Altogether, these experiments suggest that cell-to-cell
spread of BVDV depends on the use of coreceptors for free virus entry or a specialized
set of receptors.
As an alternative approach, we used CRIB cells as target cells in the coculture assay.
CRIB cells are bovine cells derived from MDBK cells that, despite expressing CD46 on
the surface, are nonsusceptible to BVDV infection due to a specific block of virus entry
(45–47). We verified that CRIB cells were resistant to infection with BVDV by using an
immunofluorescence assay to detect infected cells. In addition, recovery of infectious
viruses after transfection of CRIB cells with in vitro-transcribed BVDV RNA confirmed
that the cell line was permissive for virus replication (data not shown). Coculture of
producer cells with CRIB cells stably expressing GFP showed that BVDV was not able to
spread to CRIB cells, probably because of the lack of coreceptors that function in
cell-associated spread on the target cell surface (Fig. 7E). Altogether, these results
indicate that direct cell-to-cell transmission of BVDV requires receptor recognition on
the target cell.
To study whether direct cell-to-cell transmission involves endocytosis of spreading
viruses by the target cell, we analyzed spreading by using cocultures of producer cells
and target cells expressing a control or dominant negative construct of Eps15 in the
presence of neutralizing serum. We found that spreading to cells expressing the control
construct was efficient. In contrast, the virus was not able to spread to target cells
expressing the dominant negative construct, suggesting the requirement for clathrin-
mediated endocytosis for direct cell-to-cell transmission of BVDV (Fig. 7F and G).
DISCUSSION
Direct cell-to-cell transmission of virus infections has emerged in recent years as a
common theme in virus spread. Different viruses use disparate mechanisms of cell-to-
cell transmission that usually rely on the assembly and exit of progeny virus (reviewed
in references 26 and 27). Since assembled progeny viruses spread infection through the
extracellular space, understanding the mechanisms supporting direct cell-to-cell versus
cell-free transmission often requires suppressing free diffusion of viruses. Thus, cell
culture models of virus spread in the presence of neutralizing antibodies that com-
pletely block cell-free virus are often used to study direct cell-to-cell transmission. Based
on the dominance of BVDV E2 as an antigen in infected cattle, we expressed a
recombinant version of E2 and generated neutralizing antibodies that were shown to
completely block BVDV infection. We showed that BVDV spread in cultured MDBK
epithelial cells was resistant to antibody neutralization when virus infection was
initiated from either a virus stock or RNA transfection, thus providing evidence for
direct cell-to-cell transmission of BVDV. Furthermore, resistance to antibody neutraliza-
tion has been related to the use of tight cell-cell contacts for transmission. Confluent
MDBK cells have well-developed adherens junctions and tight junctions (48), and in
support of spreading through epithelial cell-cell contacts, we observed that spread was
completely blocked by neutralizing antibodies when infected and uninfected cells were
physically separated in a transwell coculture system.
Our study was based on the use of a pair of recombinant cp and ncp biotypes of the
NADL strain of BVDV that carry a fusion of mCherry to the major envelope protein on
the virus surface (E2), referred to as BVDV/mCherry-E2. In agreement with previous
work reporting the insertion of small tags (such as the FLAG epitope or the 11-amino-
acid subunit derived from NanoLuc luciferase) at this site (42, 43), we showed that
insertion of mCherry yielded fully infectious virus particles. Furthermore, BVDV/
mCherry-E2 used the authentic entry pathway of BVDV, as shown by comparing the
effects of pharmacological and molecular inhibitors of virus entry on parental and
recombinant viruses, indicating that the virus would be able to accommodate the
foreign protein without compromising the function of E2. Therefore, this site of
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insertion could be used to label virus particles that may aid in the study of pestivirus
biology as well as the design of marker vaccine strains that allow differentiation of
infected from vaccinated animals. Here we used only mCherry expression as a reporter
for BVDV infection. Further characterization of our recombinant virus is still required to
assess the potential for use in studies at the single-particle level.
To gain insight into the mechanisms that support spread of BVDV in cell culture, we
used a fluorescence microscopy-based assay to unequivocally quantify spread from an
infected to an uninfected cell. Our approach combined the coculture of producer cells
infected with reporter BVDV/mCherry-E2 and target cells expressing GFP or GFP fusion
proteins with automated image analysis. First, to estimate the contribution of cell-to-
cell transmission to BVDV spread, we compared spreading in a control assay and that
in the presence of neutralizing antibodies and found that antibody-resistant spread is
the main mechanism contributing to propagation of BVDV infection in cell culture. This
was the case for both the cp and ncp biotypes of BVDV, and differences in the absolute
percentages of spreading between cp and ncp viruses can be attributed to the
differences in replication kinetics of the two biotypes. Second, using complementary
approaches, we showed the use of virus receptors for direct cell-to-cell spread. Even so,
we observed that the BVDV receptor CD46 was dispensable for cell-associated spread
of the virus. Interestingly, it was recently reported that receptors mediating attachment
of free virus are dispensable for HCV cell-to-cell transmission, while postattachment
receptors are required for both cell-free and cell-to-cell transmission (35–38). CD46 is
the only identified BVDV receptor, and overexpression of CD46 in heterologous cell
lines increases the attachment of BVDV, although it is not sufficient to turn cells
susceptible to infection (8, 20). Moreover, evidence indicates that CD46 is not endo-
cytosed (49). Therefore, it is possible that it functions as an attachment receptor for free
viruses and that it is not required for cell-to-cell transmission, which depends on the
use of postattachment receptors or coreceptors. Since E2 is the viral protein responsible
for virus-receptor interaction, blocking of cell-to-cell transmission by use of soluble E2
suggests that E2 is required for cell-associated spread. In addition, the defect for direct
transmission into CRIB cells indicates that virus receptors need to be recognized on the
surfaces of target cells. Finally, using target cells expressing control and dominant
negative constructs of Eps15, we determined that, as in the case of free viruses,
infection of target cells depends on clathrin-mediated endocytosis. Overall, we dem-
onstrated that BVDV uses direct cell-to-cell transmission as the main mode to propa-
gate infection, and we showed that similar to entry of free viruses, this mode of
propagation exploits cellular endocytic pathways dependent on clathrin.
Antibodies against BVDV prevent disease development following challenge. How-
ever, after exposure to the homologous virus, viremia and shedding of BVDV in nasal
secretions still occur in the presence of serum neutralizing antibodies, suggesting that
BVDV has developed strategies to overcome the host antibody response (17, 18). Thus,
the demonstration of BVDV spread in the presence of neutralizing antibodies in cell
culture sheds new light on the mechanisms employed by BVDV to evade antibody
responses in immunocompetent adult animals. Direct cell-to-cell transmission can also
explain the ability of ncp virus to cross the placental barrier and reach the fetus. In
acute infection with BVDV, the virus is commonly isolated from peripheral blood
mononuclear cells (PBMCs). Similar to transmission of HIV across the trophoblast layer
of the placenta (50, 51), we speculate that the process of fetal infection may involve
initial cell-to-cell transmission between infected PBMCs and trophoblasts.
Altogether, we propose a mechanism for BVDV cell-to-cell transmission that involves
the egress of assembled virus particles in exocytic vesicles and their accumulation in
the extracellular space at sites of cell-cell contact (52). Envelope glycoprotein E2 on the
surfaces of extracellular viruses attached to the plasma membrane engages a cellular
coreceptor on the target cell that mediates internalization of spreading virions by
clathrin-dependent endocytosis.
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Cells and viruses. MDBK (CCL-22) and CRIB (CRL-11883) cells were purchased from ATCC and grown
in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (maintenance
medium [MM]) and antibiotics under 5% CO2 at 37°C. For infections, cells were cultivated in DMEM
supplemented with 2% horse serum (infection medium [IM]) and antibiotics under 5% CO2 at 37°C.
Spodoptera frugiperda Sf9 cells were grown in EX-Cell 420 serum-free medium (Sigma) supplemented
with antibiotic-antimycotic (Gibco) at 28°C.
Infectious viral particles of the cpBVDV strain NADL were obtained from the pACNR/NADL infectious
cDNA clone (kindly provided by Charles Rice, The Rockefeller University) by reverse genetics (44). Briefly,
cDNA infectious clones were linearized at the SbfI restriction site and were used as templates for in vitro
transcription by use of T7 RNApol (Ambion) according to the manufacturer’s instructions. Synthetic RNAs
were transfected into MDBK cells by use of Lipofectamine 2000 (Invitrogen), and infectious BVDV
particles were recovered from the cell culture supernatant after 48 h. Virus titers were determined using
an endpoint dilution assay on MDBK cells in 96-well plates, and viral stocks were stored at 70°C until
use.
Construction of cp- and ncpBVDV/mCherry-E2. A synthetic sequence containing a unique XbaI site
upstream of the first 372 nucleotides (nt) of E2 was designed (Genescript) and cloned into the pGEM-T
Easy vector (Promega). Next, the region upstream of E2 in the BVDV genome was amplified from the
pACNR/NADL infectious clone by use of primers Fw 12 and Rv 20 (Table 1) and cloned into the previous
vector by use of SphI and XbaI sites, thus giving the pGEM/SphI-5=BVDV-XbaI-E2-RsrII vector. The next
step consisted of cloning the mCherry sequence in frame with E2. Since the wild-type sequence of
mCherry in pRSET-B mCherry (53) contains an SbfI site, which is used to linearize the infectious clone for
in vitro transcription, it was necessary to remove the site by means of a silent mutation generated by
restriction-free cloning (54) using primers Fw 75 and Rv 76. The mCherry sequence was then amplified
by use of primers Fw 65 and Rv 66 and cloned between XbaI and EcoRI sites in pGEM/SphI-5=BVDV-XbaI-
E2-RsrII to generate the pGEM/SphI-5=BVDV-XbaI-mCherry-E2-RsrII vector. The sequence between the SphI
and RsrII sites was subcloned into the pACNR/NADL infectious clone to obtain cpBVDV/mCherry-E2.
In order to generate a noncytopathic version of the mCherry-E2-expressing virus, a 270-bp fragment
corresponding to the Jiv90 cellular protease sequence, which is located within NS2, was deleted (44).
Regions upstream and downstream of the Jiv90 sequence were amplified by use of primers Fw 31 and
Rv 39 and primers Fw 38 and Rv 25, respectively. Primers Rv 39 and Fw 38 contained complementary
regions that allowed us to obtain the NS2-NS3 region without the Jiv90 sequence by fusion PCR. This
fragment was cloned into the pGEM-T Easy vector, and in order to generate a sequence with a unique
BglII site, the BglII site in the NS2 coding sequence was removed by restriction-free cloning using primers
Fw 45 and Rv 46. Finally, the NS2-NS3 ΔJiv90 construct was cloned into the pBVDV/mCherry-E2 infectious
clone between BglII and NsiI sites, replacing the wild-type sequence.
Stocks of cp- and ncpBVDV/mCherry-E2 were produced using reverse genetics.
Recombinant E2 expression and purification. The E2 sequence was amplified from the pACNR/
NADL infectious cDNA clone without its transmembrane domain, and carrying a 6-histidine sequence in
frame with E2, by use of primers Fw 1 and Rv 3. The PCR product was cloned between SmaI and PstI
restriction sites downstream of the baculovirus GP64 signal peptide sequence in the transfer vector
pFBSD (derived from pFastBac1 [Invitrogen], a kind gift of Oscar Taboga, Instituto de Virología, INTA).
Thus, we generated the transfer vector pFBSD/ps-E2Δ-6His, which codes for a soluble and secretable
version of E2 tagged with a 6His epitope and was transformed into Escherichia coli DH10BAC cells
(Invitrogen) to generate a recombinant bacmid DNA carrying the E2 gene expression cassette. For
recombinant baculovirus generation, 7  105 Sf9 cells were seeded into 6-well plates and transfected
with bacmid DNA by use of Lipofectamine 3000 reagent (Invitrogen) according to the manufacturer’s
protocol. After 5 days of incubation at 28°C, the supernatant was harvested and clarified. For viral titer
amplification, successive rounds of infection of Sf9 cells were performed. Infectious virus titers were
calculated by endpoint dilution assay, using the method of Reed and Muench, and converted to PFU per
TABLE 1 Primers used in this study
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milliliter as described by O’Reilly et al. (55). In order to verify that recombinant E2 was efficiently secreted,
a fraction of the clarified supernatant was boiled in the presence of 1 cracking buffer (2% SDS, 10%
glycerol, 60 mM Tris-HCl, pH 6.8, 0.1 M dithiothreitol [DTT]), and proteins were resolved by SDS-PAGE.
Recombinant proteins were detected by Western blotting, employing both anti-6His epitope tag
(Rockland) and anti-BVDV antibodies. For final protein production, five T175 flasks were seeded with
2  107 Sf9 cells each and infected at a multiplicity of infection (MOI) of 5. E2 purification was performed
with a Ni-Sepharose high-performance column (GE Healthcare) according to the manufacturer’s instruc-
tions. Briefly, clarified supernatants were pooled and dialyzed into IMAC buffer (50 mM Tris, pH 7.6,
500 mM NaCl, 20 mM imidazole). After loading, protein fractions were eluted in a step gradient of
imidazole and analyzed by SDS-PAGE and Coomassie blue staining.
Fluorescence microscopy. MDBK cells were seeded on glass coverslips at a density of 105 cells/well
in 24-well plates and infected at an MOI of 0.1. At the indicated times after infection, cells were
thoroughly washed and fixed using 4% paraformaldehyde (PFA). To analyze the correlation between
mCherry and NS3 expression after infection with the cpBVDV/mCherry-E2 reporter, fixed samples were
first incubated with a mouse antibody against NS3 and then washed three times in phosphate-buffered
saline (PBS) before addition of an Alexa Fluor-conjugated secondary antibody. Cell nuclei were stained
with DAPI (4=,6-diamidino-2-phenylindole), and coverslips were then mounted onto glass slides by use
of FluoroGuard antifade reagent (Bio-Rad). Samples were visualized under a Nikon Eclipse 80i fluores-
cence microscope equipped with a DS-Qi1Mc camera and analyzed with ImageJ software.
Confocal microscopy. Colocalization between mCherry and E2 in cells infected with cpBVDV/
mCherry-E2 was assessed by confocal microscopy. Infected cells were fixed, stained with a monoclonal
antibody against E2 (DMAB28412; Creative Diagnostics), and mounted onto glass slides. Images were
acquired in a microscope with an inverted Olympus IX 81 module and a confocal FV1000 module with
a Plan ApoN60X/1.42 objective controlled by the FV10-ASW 3.1 software program and were analyzed
with ImageJ software.
BVDV entry assays. Monoclonal antibodies (MAbs) BVD/CA 17 and 26 against CD46 (56) were a kind
gift from Till Rümenapf, University of Veterinary Medicine Austria. The effective concentrations for the
inhibition of BVDV infection with recombinant E2 and CD46 MAbs were estimated in a cytopathic effect
reduction assay (57). The inhibitory effect on virus entry was tested on MDBK cell monolayers incubated
with recombinant E2 (1 g/ml) and CD46 MAbs (3 g/ml) for 1 h before infection with BVDV. Cells were
thoroughly washed at 2 h, and the infection was allowed to proceed for 24 h. Fixed cells were stained
and analyzed by fluorescence microscopy.
Drugs used in entry assays were first tested for cytotoxicity in MDBK cells. Cells in 96-well plates were
incubated for 3 h with increasing amounts of drugs and rinsed twice with PBS, and after 72 h at 37°C,
viability was measured using crystal violet staining as previously described (57).
To test the effects of drugs on BVDV entry, MDBK cells were preincubated for 1 h with increasing
amounts of NH4Cl (10 to 50 mM) or chlorpromazine (5 to 25 M) (Sigma) in 200 l of IM. Cells were then
infected with BVDV for 2 h with the same amount of drug in the medium and rinsed 3 times with PBS,
and after 24 h, the cells were fixed and visualized by fluorescence microscopy.
Lentivirus transduction and cell sorting. Due to the impossibility of transfecting MDBK cells with
DNA, we used lentivirus transduction to express foreign proteins.
First, lentivirus transfer vectors coding for Eps15 DIIIΔ2 and Eps15 EH29 fused to GFP were con-
structed by subcloning the fragment between NheI and blunt-ended XbaI sites of the corresponding
Eps15 constructs (58) into NheI and blunt-ended EcoRI sites of pLB (Addgene plasmid 11619).
To produce lentivirus, the transfer vector pLB coding for GFP, GFP-Eps15 DIIIΔ2, or GFP-Eps15 EH29
was cotransfected with the packaging vector pSPAX2 (Addgene plasmid 12260) and the vesicular
stomatitis virus glycoprotein vector pMD2.G (Addgene plasmid 12259) into 293T cells by use of
Lipofectamine 2000 according to the manufacturer’s instructions. Supernatant with lentivirus was
collected from one 10-cm dish 3 days after transfection, and low-speed concentration was performed by
overnight centrifugation of the viral supernatant at 3,000  g and 4°C. Concentrated viral supernatants
were supplemented with 20 mM HEPES, pH 7.4, and 10 g/ml Polybrene (Sigma).
For MDBK transduction, 3  105 cells were seeded into 6-well plates. The following day, cells were
washed with PBS and infected with lentiviruses by centrifugation at 2,500 rpm at 30°C for 30 min. After
4 h of incubation at 37°C, the medium was removed and complete fresh medium was added. GFP
expression at 48 h was evaluated by fluorescence microscopy. Due to the low transduction efficiency of
MDBK cells (5% to 10%), a round of enrichment of the cells expressing GFP was performed by cell sorting
in a FACSAria II flow cytometer (BD Biosciences) to obtain a cell line with over 80% GFP-expressing cells.
In order to verify loss of function of clathrin-mediated endocytosis by expression of dominant
negative Eps15, internalization of Texas Red-conjugated human transferrin (Rockland) into MDBK cells
expressing GFP-Eps15 DIIIΔ2 or GFP-Eps15 EH29 was measured by fluorescence microscopy. Cells were
serum starved for 30 min, incubated for 45 min with 15 g/ml transferrin in serum-free medium at 37°C,
rinsed three times with PBS, fixed with 4% PFA, and imaged.
BVDV neutralizing serum production and IgG purification. The purified recombinant E2 protein
was used to generate a specific polyclonal antiserum. Four female mice of the CF1 strain were
immunized following a standard immunization protocol. Briefly, mice were injected via the intra-
peritoneal route on days 0, 17, and 32, and sera were obtained at day 45. The first dose consisted
of 2.5 g of purified recombinant E2 mixed with an equal volume of Freund’s complete adjuvant.
The second and third doses consisted of 1.25 g of protein mixed with an equal volume of Freund’s
incomplete adjuvant. All mice were bred in accordance with institutional animal guidelines under
specific pathogen-free conditions in the local animal facility of the Instituto de Investigaciones
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Biotecnológicas at the Universidad Nacional de San Martín. Mouse experimentation was approved
by the local regulatory agencies (CICUAE-UNSAM).
Antibodies of the IgG isotype were purified from the serum by affinity chromatography. The serum
was filtered through a 0.22-m-pore-size cellulose acetate membrane and loaded into a HiTrap protein
G HP column (GE Healthcare) equilibrated with binding buffer (20 mM sodium phosphate, 150 mM
sodium chloride). After washing with 10 column volumes of binding buffer, bound IgG antibodies were
eluted in 10 column volumes of 0.1 M glycine, pH 2.5, and collected in 1-ml fractions in tubes containing
85 l 1 M Tris base. The eluted fractions were assayed for IgG heavy and light chains by SDS-PAGE and
Coomassie blue staining. The fractions containing IgG antibodies were pooled, dialyzed into PBS, and
concentrated by Centricon filtration.
Titration of neutralizing antibodies. Neutralizing titers were estimated by cytopathic effect reduc-
tion assays with the neutralizing serum, the purified IgG fraction, and an anti-BVDV MAb (DMAB28412;
Creative Diagnostics) raised against E2. Briefly, wild-type cpBVDV was preincubated with serial dilutions
of serum or antibodies for 30 min in infection medium. Virus was then added to a confluent MDBK cell
monolayer in a 96-well microplate. After 72 h of incubation, cells were fixed and stained with a crystal
violet solution (0.1% crystal violet, 20% ethanol) to measure the extent of cytopathic effect. The
neutralizing antibody titer was estimated as the serum dilution capable of inhibiting the BVDV cytopathic
effect by 90% (NT90) compared to the control level.
Transwell coculture assay. MDBK cells were seeded on coverslips in a 24-well plate in the
presence of 300 l of infection medium or medium supplemented with neutralizing serum (1:500).
In a separate plate, 3  104 MDBK cells were seeded on transwell polycarbonate membrane inserts
with a 3-m pore size (Corning), infected with ncpBVDV/mCherry-E2, and in turn cocultured with
noninfected cells. After 48 h of incubation at 37°C, cells were fixed and processed for visualization
by fluorescence microscopy.
Spreading assays in coculture systems. A coculture system to measure direct cell-to-cell transmis-
sion of the viral infection from infected cells to target noninfected cells was developed. To this end, we
generated an MDBK cell line stably infected with ncpBVDV/mCherry-E2. MDBK cells were infected with
the noncytopathic reporter virus, and after several passages, mCherry expression and the presence of
infectious BVDV particles in the supernatant were successfully verified. Cocultures were set up by mixing
infected producer cells (MDBK-mCherry) and labeled target cells expressing GFP or GFP fusion proteins
(MDBK-GFP) at a 1:4 ratio. Cells were seeded on coverslips at a density of 105 cells/well in 500 l infection
medium supplemented with neutralizing antibodies and incubated for 72 h before processing of the
samples for fluorescence microscopy analysis. To measure spreading cpBVDV/mCherry-E2, MDBK cells
were seeded on coverslips at a density of 30,000 cells/well and infected at an MOI of 3. At 2 h
postinfection, cells were extensively washed, and MDBK-GFP cells were plated onto infected cells at a
density of 105 cells/well in 500 l IM supplemented with neutralizing antibodies. Cocultures were fixed
at 48 h and imaged as described below.
Computer-assisted image analysis. The number of virus-infected cells was determined by using the
analytical tools of ImageJ software. The appropriate threshold for the red channel identified objects
corresponding to mCherry expression in cpBVDV/mCherry-E2-infected cells. We next used the dilate tool
and the particle analyzer to filter objects according to size and shape and to create a mask displaying
only infected cells. Finally, we counted the number of cells obtained according to the filter.
Statistical analysis. Results represent independent repeats of the experiments, and statistical
analyses were performed with GraphPad Prism 5 software. Inhibition plots were adjusted by nonlinear
fitting, and columns in bar graphs were compared by the unpaired t test or by one-way analysis of
variance (ANOVA) with the Dunnett’s posttest.
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